Chronic Kidney Disease Clinical Trial
— OPPORTUNITYOfficial title:
Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.
The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on
survival (primary end-point; "time to death" and health related quality of life in adult
patients on chronic haemodialysis.
Status | Terminated |
Enrollment | 712 |
Est. completion date | December 2008 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Serum albumin as specified in protocol - Malnourished (based on serum albumin value below 40 g/L, assessed centrally) - Stable (for 3 months or more) and adequate haemodialysis treatment three months prior to enrolment as defined by Kt/V of more than 1.2 Exclusion Criteria: - Active malignant disease - Critical illness requiring treatment in an intensive care unit (ICU) - Uncontrolled treated/untreated hypertension - Patients on chronic (more than 3 months) treatment with steroids in doses of more than 10 mg/day prednisolone (or equivalent) - Patients treated with immunosuppressive agents - Known Growth Hormone Deficiency - Patients suffering from any clinically significant disease history in the opinion of the investigator - Severe illness as defined in the protocol (as judged by the investigator) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Puerto Rico | Novo Nordisk Clinical Trial Call Center | Ponce | |
United States | Novo Nordisk Clinical Trial Call Center | Alexander City | Alabama |
United States | Novo Nordisk Clinical Trial Call Center | Alexandria | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | Allentown | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Arlington | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Atlanta | Georgia |
United States | Novo Nordisk Clinical Trial Call Center | Augusta | Georgia |
United States | Novo Nordisk Clinical Trial Call Center | Baton Rouge | Louisiana |
United States | Novo Nordisk Clinical Trial Call Center | Bend | Oregon |
United States | Novo Nordisk Clinical Trial Call Center | Bethesda | Maryland |
United States | Novo Nordisk Clinical Trial Call Center | Beverly Hills | California |
United States | Novo Nordisk Clinical Trial Call Center | Billings | Montana |
United States | Novo Nordisk Clinical Trial Call Center | Birmingham | Alabama |
United States | Novo Nordisk Clinical Trial Call Center | Bluefield | West Virginia |
United States | Novo Nordisk Clinical Trial Call Center | Boise | Idaho |
United States | Novo Nordisk Clinical Trial Call Center | Boston | Massachusetts |
United States | Novo Nordisk Clinical Trial Call Center | Brandon | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Brockton | Massachusetts |
United States | Novo Nordisk Clinical Trial Call Center | Bronx | New York |
United States | Novo Nordisk Clinical Trial Call Center | Bronx | New York |
United States | Novo Nordisk Clinical Trial Call Center | Brooklyn | New York |
United States | Novo Nordisk Clinical Trial Call Center | Buffalo | New York |
United States | Novo Nordisk Clinical Trial Call Center | Buffalo | New York |
United States | Novo Nordisk Clinical Trial Call Center | Burlington | Vermont |
United States | Novo Nordisk Clinical Trial Call Center | Chesapeake | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | Chula Vista | California |
United States | Novo Nordisk Clinical Trial Call Center | Clarksville | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | Colorado Springs | Colorado |
United States | Novo Nordisk Clinical Trial Call Center | Columbus | Mississippi |
United States | Novo Nordisk Clinical Trial Call Center | Columbus | Ohio |
United States | Novo Nordisk Clinical Trial Call Center | Cooperstown | New York |
United States | Novo Nordisk Clinical Trial Call Center | Coral Springs | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Corpus Christi | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Corpus Christi | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Covina | California |
United States | Novo Nordisk Clinical Trial Call Center | Crestwood | Illinois |
United States | Novo Nordisk Clinical Trial Call Center | Dallas | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Denver | Colorado |
United States | Novo Nordisk Clinical Trial Call Center | Des Moines | Iowa |
United States | Novo Nordisk Clinical Trial Call Center | Detroit | Michigan |
United States | Novo Nordisk Clinical Trial Call Center | Durham | North Carolina |
United States | Novo Nordisk Clinical Trial Call Center | Dyersburg | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | Easton | Maryland |
United States | Novo Nordisk Clinical Trial Call Center | Eatontown | New Jersey |
United States | Novo Nordisk Clinical Trial Call Center | Eldorado | Arkansas |
United States | Novo Nordisk Clinical Trial Call Center | Evergreen Park | Illinois |
United States | Novo Nordisk Clinical Trial Call Center | Fairfax | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | Fresh Meadows | New York |
United States | Novo Nordisk Clinical Trial Call Center | Glendale | Wisconsin |
United States | Novo Nordisk Clinical Trial Call Center | Glendale | Arizona |
United States | Novo Nordisk Clinical Trial Call Center | Glendale | California |
United States | Novo Nordisk Clinical Trial Call Center | Greenville | North Carolina |
United States | Novo Nordisk Clinical Trial Call Center | Gulfport | Mississippi |
United States | Novo Nordisk Clinical Trial Call Center | Gurnee | Illinois |
United States | Novo Nordisk Clinical Trial Call Center | Hagerstown | Maryland |
United States | Novo Nordisk Clinical Trial Call Center | Hampton | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | Hot Springs | Arkansas |
United States | Novo Nordisk Clinical Trial Call Center | Houston | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Indianapolis | Indiana |
United States | Novo Nordisk Clinical Trial Call Center | Jackson | Mississippi |
United States | Novo Nordisk Clinical Trial Call Center | Johnstown | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Kalamazoo | Michigan |
United States | Novo Nordisk Clinical Trial Call Center | Kearney | Nebraska |
United States | Novo Nordisk Clinical Trial Call Center | Killeen | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Knoxville | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | Knoxville | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | La Mesa | California |
United States | Novo Nordisk Clinical Trial Call Center | Lafayatte | Louisiana |
United States | Novo Nordisk Clinical Trial Call Center | Lakewood | California |
United States | Novo Nordisk Clinical Trial Call Center | Lewistown | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Lexington | Kentucky |
United States | Novo Nordisk Clinical Trial Call Center | Los Alamitos | California |
United States | Novo Nordisk Clinical Trial Call Center | Los Angeles | California |
United States | Novo Nordisk Clinical Trial Call Center | Lubbock | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Lynwood | California |
United States | Novo Nordisk Clinical Trial Call Center | Macon | Georgia |
United States | Novo Nordisk Clinical Trial Call Center | Madisonville | Kentucky |
United States | Novo Nordisk Clinical Trial Call Center | Marietta | Georgia |
United States | Novo Nordisk Clinical Trial Call Center | Maywood | Illinois |
United States | Novo Nordisk Clinical Trial Call Center | McGehee | Arkansas |
United States | Novo Nordisk Clinical Trial Call Center | Meadville | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Medford | Oregon |
United States | Novo Nordisk Clinical Trial Call Center | Merced | California |
United States | Novo Nordisk Clinical Trial Call Center | Meridian | Idaho |
United States | Novo Nordisk Clinical Trial Call Center | Miami | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Michigan City | Indiana |
United States | Novo Nordisk Clinical Trial Call Center | Middlebury | Connecticut |
United States | Novo Nordisk Clinical Trial Call Center | Milwaukee | Wisconsin |
United States | Novo Nordisk Clinical Trial Call Center | Mission Hills | California |
United States | Novo Nordisk Clinical Trial Call Center | Mobile | Alabama |
United States | Novo Nordisk Clinical Trial Call Center | Mobile | Alabama |
United States | Novo Nordisk Clinical Trial Call Center | Monterey Park | California |
United States | Novo Nordisk Clinical Trial Call Center | Mountain View | California |
United States | Novo Nordisk Clinical Trial Call Center | Nashville | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | Nashville | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | Nashville | Tennessee |
United States | Novo Nordisk Clinical Trial Call Center | Neenah | Wisconsin |
United States | Novo Nordisk Clinical Trial Call Center | New Iberia | Louisiana |
United States | Novo Nordisk Clinical Trial Call Center | New York | New York |
United States | Novo Nordisk Clinical Trial Call Center | New York | New York |
United States | Novo Nordisk Clinical Trial Call Center | New York | New York |
United States | Novo Nordisk Clinical Trial Call Center | Norfolk | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | North Charleston | South Carolina |
United States | Novo Nordisk Clinical Trial Call Center | North Platte | Nebraska |
United States | Novo Nordisk Clinical Trial Call Center | Orangeburg | South Carolina |
United States | Novo Nordisk Clinical Trial Call Center | Orlando | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Oshkosh | Wisconsin |
United States | Novo Nordisk Clinical Trial Call Center | Panama City | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Paragould | Arkansas |
United States | Novo Nordisk Clinical Trial Call Center | Pembroke Pines | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Philadelphia | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Philadelphia | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Phoenix | Arizona |
United States | Novo Nordisk Clinical Trial Call Center | Pine Bluff | Arkansas |
United States | Novo Nordisk Clinical Trial Call Center | Pittsburg | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Pittsburgh | Pennsylvania |
United States | Novo Nordisk Clinical Trial Call Center | Port Washington | New York |
United States | Novo Nordisk Clinical Trial Call Center | Porterville | California |
United States | Novo Nordisk Clinical Trial Call Center | Portsmouth | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | Provo | Utah |
United States | Novo Nordisk Clinical Trial Call Center | Riverside | California |
United States | Novo Nordisk Clinical Trial Call Center | Rockville | Maryland |
United States | Novo Nordisk Clinical Trial Call Center | Roseburg | Oregon |
United States | Novo Nordisk Clinical Trial Call Center | Sacramento | California |
United States | Novo Nordisk Clinical Trial Call Center | Salem | Virginia |
United States | Novo Nordisk Clinical Trial Call Center | San Antonio | Texas |
United States | Novo Nordisk Clinical Trial Call Center | San Antonio | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Santee | South Carolina |
United States | Novo Nordisk Clinical Trial Call Center | Shreveport | Louisiana |
United States | Novo Nordisk Clinical Trial Call Center | Springfield | Massachusetts |
United States | Novo Nordisk Clinical Trial Call Center | St. Ann | Missouri |
United States | Novo Nordisk Clinical Trial Call Center | St. Louis | Missouri |
United States | Novo Nordisk Clinical Trial Call Center | St. Louis | Missouri |
United States | Novo Nordisk Clinical Trial Call Center | St. Peters | Missouri |
United States | Novo Nordisk Clinical Trial Call Center | Sumter | South Carolina |
United States | Novo Nordisk Clinical Trial Call Center | Tampa | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Tampa | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Tempe | Arizona |
United States | Novo Nordisk Clinical Trial Call Center | Toledo | Ohio |
United States | Novo Nordisk Clinical Trial Call Center | Topeka | Kansas |
United States | Novo Nordisk Clinical Trial Call Center | Torrance | California |
United States | Novo Nordisk Clinical Trial Call Center | Tucson | Arizona |
United States | Novo Nordisk Clinical Trial Call Center | Tuscon | Arizona |
United States | Novo Nordisk Clinical Trial Call Center | Tyler | Texas |
United States | Novo Nordisk Clinical Trial Call Center | Vacaville | California |
United States | Novo Nordisk Clinical Trial Call Center | Visalia | California |
United States | Novo Nordisk Clinical Trial Call Center | Voorhees | New Jersey |
United States | Novo Nordisk Clinical Trial Call Center | Walnut Creek | California |
United States | Novo Nordisk Clinical Trial Call Center | Washington | District of Columbia |
United States | Novo Nordisk Clinical Trial Call Center | Weston | Florida |
United States | Novo Nordisk Clinical Trial Call Center | Whittier | California |
United States | Novo Nordisk Clinical Trial Call Center | Whittier | California |
United States | Novo Nordisk Clinical Trial Call Center | Wichita | Kansas |
United States | Novo Nordisk Clinical Trial Call Center | Yonkers | New York |
United States | Novo Nordisk Clinical Trial Call Center | Yuba City | California |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
United States, Argentina, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Italy, Poland, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Sweden, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality - Time to All-cause Death | Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks. | week 0, trial termination | Yes |
Secondary | Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event) | Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks. | week 0, trial termination | Yes |
Secondary | Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures | The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated. | week 0, trial termination | No |
Secondary | Mortality - Two-year Mortality Rate | week 0, trial termination | No | |
Secondary | Health Related Quality of Life Assessments | Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction. | week 0, trial termination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |